Int. J. Chem. Sci.: 7(4), 2009, 2239-2245

PREPARATION AND EVALUATION OF CROSS LINKED STARCH UREA - A NEW POLYMER FOR CONTROLLED RELEASE OF DICLOFENAC

K. P. R. CHOWDARY* and D. UDAYA CHANDRA

University College of Pharmaceutical Sciences, Andhra University,
VISAKHAPATNAM – 530 003 (A.P.) INDIA

ABSTRACT

In present investigation, cross linked starch – urea, a new starch based polymer has been synthesized and its application in controlled release (CR) and in the design of diclofenac controlled release tablets has been evaluated. Cross-linked starch-urea polymer was synthesized by gelatinization of starch in the presence of urea and crosslinking by treatment with calcium chloride. Matrix tablets each containing 100 mg of diclofenac were formulated employing (i) starch-urea and (ii) cross-linked starch-urea in different proportions by wet granulation method and the tablets were evaluated. Cross-linked starch-urea was more suitable than starch-urea for controlled release application. Diclofenac release from the matrix tablets formulated employing cross-linked starch-urea was slow, spread over 24 h and the release was diffusion controlled. Non – Fickian diffusion was the drug release mechanism from these matrix tablets. Diclofenac release from matrix tablets (F4) formulated employing 66 % cross-linked starch–urea was similar to that from Voveran SR tablets, a commercial SR formulation of diclofenac. Diclofenac CR tablets for once-a-day (24 h) administration could be designed employing cross-linked starch-urea.

Key words: Cross-linked starch-urea, Controlled release, Diclofenac, Matrix tablets.

INTRODUCTON

In the last two decades, controlled- release dosage forms have made significant progress in terms of clinical efficacy and patient compliance. Drug release from these systems should be at a desire rate, predictable and reproducible. Polymers, which are used as release – retarding materials in the design of controlled – release dosage forms play a vital role in controlling the delivery of drug from these dosage forms. Though a wide range of polymers and other release- retarding materials are available, there is a continued need to

*Author for correspondence; E-mail: profkprc@rediffmail.com

develop new, safe and effective release – retarding polymers for controlled release. Starch is a natural, biodegradable polymer and modified starches are reported as fillers[1], disintegrants, dry binders and matrix formers for controlled release[2,3]. Starch reacts with urea to form starch – urea (carbamate), a hydrophilic water swellable polymer. In the present study, starch-urea and cross-linked starch-urea (a new modified starch) were prepared and evaluated for their application in the design of controlled release tablets of diclofenac. Among the various approaches, preparation of drug-embedded matrix tablet is one of the least complicated approach for obtaining controlled release. Hence, formulation of matrix tablets is aimed in the present study for obtaining controlled release. Diclofenac containing matrix tablets were prepared employing (i) starch-urea and (ii) cross linked starch-urea and were evaluated for controlled release (CR) and to design diclofenac CR tablets. Controlled release formulation is needed for diclofenac because of its short biological half life[4] of 2.0 h and also to minimize the g.i. disturbances such as peptic ulceration with bleeding, if present in larger concentration in g.i. tract[5].

EXPERIMENTAL

Materials

Diclofenac sodium was a gift sample from M/s. Micro Labs Ltd., Pondicherry. All other materials used were of Pharmacopoeial grade.

Methods

Preparation of starch-urea

Potato starch (9 parts) was dispersed in purified water (10 parts) to form starch slurry. Urea (1 part) was dissolved in purified water (40 parts) and the solution was heated to boiling. While boiling, the starch slurry was added and mixed. Mixing while heating was continued for 20 minutes to form starch-urea polymer. The mass formed was spread on to a stainless steel plate and dried at 85^0C for 6-8 h. The dried polymer was powdered and passed through mesh No. 100.

Preparation of cross-linked starch-urea polymer

Potato starch (9 parts) was dispersed in purified water (10 parts) to form starch slurry. Urea (1 part) and calcium chloride (1 part) were dissolved in purified water (40 parts) and the solution was heated to boiling. While boiling, the starch slurry was added and mixed. Mixing while heating was continued for 20 minutes to form cross-linked starch-urea polymer. The mass formed was spread on to a stainless steel plate and dried at 85^0C for 6-8 h. The dried polymer was powdered and passed through mesh No. 100.

Preparation of tablets

Matrix tablets each containing 100 mg of diclofenac sodium were prepared employing (i) starch-urea and (ii) cross-linked starch-urea in different proportions of drug and polymer. The required quantities of medicament and matrix materials were mixed thoroughly in a mortar by following geometric dilution technique. The binder (1% PVP solution) was added and mixed thoroughly to form dough mass. The mass was passed through mesh No. 12 to obtain wet granules. The wet granules were dried at 60^0C for 4 h. The dried granules were passed through mesh No. 16 to break aggregates. The lubricants talc (2%) and magnesium stearate (2%) were passed through mesh No. 100 on to dry granules and blended in a closed polyethylene bag. The tablet granules were compressed into tablets on a rotary multi- station punching machine (Cadmach Machinery Co. Pvt. Ltd., Mumbai) to a hardness of 8-10 kg/sq.cm. using 9 mm round and flat punches.

Hardness of tablets was tested using Monsanto hardness tester. Friability of tablets was determined in a Roche friabilator. Disintegration time was determined in a Thermonic tablet disintegration test machine using water, 0.1N HCl and phosphate buffer of pH 7.4 as test fluids.

Estimation of diclofenac

Diclofenac content of the tablets was estimated by an UV spectrophotometric method based on the measurement of absorbance at 276 nm in phosphate buffer of pH 7.4. The method was validated for linearity, precision and accuracy. The method obeyed Beer's law in the concentration range 0-10 µg/mL. When a standard drug solution was assayed repeatedly (n = 6), the mean error (accuracy) and relative standard deviation (precision) were found to be 0.6 and 0.8 %, respectively. No interference from the excipients used was observed.

Drug release study

Drug release from matrix tablets was studied using 8 station dissolution rate test apparatus (Lab India, Disso 2000) employing a paddle stirrer at 50 rpm and at 37± 1^0C. Phosphate buffer of pH 7.4 (900 mL) was used as dissolution fluid. Samples of 5 mL of each were withdrawn at different time intervals over a period of 24 h. Each sample withdrawn was replaced with an equal amount of fresh dissolution medium. Samples were suitably diluted and assayed at 276 nm for diclofenac using an Elico BL 198 double beam UV-spectrophotometer. For comparison, diclofenac release from Voveran SR tablets was also studied. The drug release experiments were conducted in triplicate.

Data analysis

Release data were analyzed as per zero order, first order, Higuchi[6] and Peppas[7] models to assess the drug release kinetics and mechanism from tablets.

RESULTS AND DISCUSSION

Starch-urea (carbamate) was prepared by gelatinizing potato starch in the presence of urea. The starch-urea was then cross linked by treatment with calcium chloride to result in cross-linked starch-urea. Both starch-urea and cross-linked starch-urea formed were found to be fine and free flowing powders upon drying and grinding. They are insoluble in water, aqueous fluids of acidic and alkaline pHs. When tested for melting point, the polymers charred at 220^0 -230^0C.

Matrix tablets each containing 100 mg of diclofenac could be prepared employing (i) starch-urea and (ii) cross-linked starch-urea in different proportions (33, 50, 66 and 75% strengths in the formulae) by wet granulation method. Hardness of the tablets was in the range of 8-10 kg/sq.cm. Weight loss in the friability test was less than 0.4 % in all the cases. All the matrix tablets prepared contained 100 ± 3% of the labeled claim. All the tablets were found to be non-disintegrating in water, aqueous, acidic (pH 1.2) and alkaline (pH 7.4) fluids. As such, the prepared tablets were of good quality with regard to drug content, hardness and friability. As the tablets formulated employing starch-urea and cross-linked starch-urea were non-disintegrating in acidic and alkaline fluids, they are considered suitable for oral controlled release.

Release parameters of the matrix tablets prepared are summarized in Table 1. Diclofenac release from the prepared tablets was slow and spread over 24 h and depended on the polymer type and concentration of cross linked starch-urea polymer in the tablets. Diclofenac release was relatively rapid in the case of matrix tablets prepared employing starch-urea polymer at 50% strength and the release was complete in 5 h. Whereas when cross-linked starch-urea polymer was used at the same strength of 50% in the formula, the release was much slow and spread over 16 h. As the concentration of cross-linked starch-urea polymer in the matrix tablets was increased, the release rate was decreased. Diclofenac release from matrix tablets (F4) formulated employing 66% cross-linked starch-urea polymer was spread over 24 h and was similar to that from Voveran SR tablets, a commercial SR product of diclofenac.

Analysis of release data as per zero order and first order kinetic models indicated that both the models are equally applicable to describe the release data. Plots of percent

Table 1 : Diclofenac release characteristics of matrix tablets formulated employing starch-urea and cross-linked starch-urea

Formulation	Polymer (%)	Percent drug release at various times (h)						T_{50} (h)	T_{90} (h)	K_0 (mg/h)	K_1 (h^{-1})	'n' in Peppas equation
		1	4	6	8	12	24					
F1	SU (50%)	26.5	90.7	100	---	---	---	1.7	3.58	21.77	0.8235	0.835
F2	CSU (33%)	43.5	72.4	100	---	---	---	1.3	4.7	18.51	0.3193	0.379
F3	CSU (50%)	12.3	35.2	51.4	70.5	91.0	---	5.8	11.8	07.28	0.1968	0.942
F4	CSU (66%)	20.6	46.6	60.4	72.8	90.7	100	4.4	12	04.42	0.2179	0.618
F5	CSU (75%)	19.2	93.6	100	---	---	---	1.8	3.6	13.05	0.7787	0.916
Voveran SR tablets	---	20.1	41.8	59.1	69.2	81.8	100	4.8	15	03.95	0.1723	0.545

SU: Starch-urea; **CSU**: Cross-linked starch-urea

release versus square root of time were found to be linear with $r > 0.9626$ with all the tablets prepared indicating that the drug release from these tablets was diffusion controlled. When the release data were analyzed as per Peppas equation, the release exponent 'n' was in the range 0.618 - 0.942 indicating non - Fickian (anomalous) diffusion as the release mechanism from all the tablets prepared except formulation F2. In the case of formulation F2, which gave rapid release of diclofenac, the 'n' was found to be 0.379 indicating Fickian diffusion as the release mechanism from these tablets.

For comparison, diclofenac release from one commercial SR brand (Voveran SR tablets) was studied. Drug release profiles of formulation F4 and Voveran SR tablets were compared by calculating difference factor f_1 and similarity factor f_2. A value of $f_1 < 15$ and $f_2 > 50$ indicate similarity of the two drug release profiles. The values of f_1 and f_2 were found to be 4.62 and 132.16, respectively for the comparison of release profiles of formulation F4 and Voveran SR tablets indicating that the release profiles of these two products are similar. Hence, matrix tablets formulated employing cross-linked starch-urea (F4) are considered suitable for controlled release of diclofenac over 24 h (i.e. once-a-day administration).

CONCLUSIONS

(i) Cross-linked starch-urea was more suitable than starch-urea for controlled release application.

(ii) Diclofenac release from the matrix tablets formulated employing cross-linked starch-urea was slow, spread over 24 h and the release was diffusion controlled.

(iii) Non – Fickian diffusion was the drug release mechanism from these matrix tablets.

(iv) Diclofenac release from the matrix tablets (F4) formulated employing 66% cross-linked starch-urea was similar to that from Voveran SR tablets, a commercial SR formulation of diclofenac.

(v) Diclofenac CR tablets for once-a-day (24 h) administration could be designed employing cross-linked starch-urea.

REFERENCES

1. M. K. Kottke, H. R. Chuech and C. T. Rhodes, Drug Dev. Ind. Pharm., **18**, 2207 (1992).

2. J. Herman and J. P. Remon, Int. J. Pharm., **63**, 201(1990).

3. K. P. R. Chowdary, P. Tripura Sundari and G. Sailaja, Int. J. Chem. Sci., **6(3)**, 1299 (2008).

4. K. A. Kobayashi, L. A. Bauer, J. R. Horn, K. Opheim, F. Jr. Wood and W. A. Kradjan, Clin. Pharm., **7**, 224 (1988).

5. H. P. Rang, M. M. Dale and J. M. Ritter, in, Pharmacology, 4th Edn., Churchill Living Stone, London , (1999) p. 230.

6. T. J. Higuchi, Pharm. Sci., **52**, 1145 (1963).

7. P. L. Ritger and N. A. Peppas, J. Control. Release, **5**, 37 (1987).

Accepted : 28.07.2009